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Abstract
Acquired immunodeficiency syndrome and tuberculosis (TB) are two of the world’s most devastating diseases. The first
vaccine the majority of infants born in Africa receive is Mycobacterium bovis bacillus Calmette-Gue ´rin (BCG) as a prevention
against TB. BCG protects against disseminated disease in the first 10 years of life, but provides a variable protection against
pulmonary TB and enhancing boost delivered by recombinant modified vaccinia virus Ankara (rMVA) expressing antigen
85A (Ag85A) of M. tuberculosis is currently in phase IIb evaluation in African neonates. If the newborn’s mother is positive for
human immunodeficiency virus type 1 (HIV-1), the baby is at high risk of acquiring HIV-1 through breastfeeding. We
suggested that a vaccination consisting of recombinant BCG expressing HIV-1 immunogen administered at birth followed
by a boost with rMVA sharing the same immunogen could serve as a strategy for prevention of mother-to-child
transmission of HIV-1 and rMVA expressing an African HIV-1-derived immunogen HIVA is currently in phase I trials in African
neonates. Here, we aim to develop a dual neonate vaccine platform against HIV-1 and TB consisting of BCG.HIVA
administered at birth followed by a boost with MVA.HIVA.85A. Thus, mMVA.HIVA.85A and sMVA.HIVA.85A vaccines were
constructed, in which the transgene transcription is driven by either modified H5 or short synthetic promoters, respectively,
and tested for immunogenicity alone and in combination with BCG.HIVA
222. mMVA.HIVA.85A was produced markerless and
thus suitable for clinical manufacture. While sMVA.HIVA.85A expressed higher levels of the immunogens, it was less
immunogenic than mMVA.HIVA.85A in BALB/c mice. A BCG.HIVA
222–mMVA.HIVA.85A prime-boost regimen induced robust
T cell responses to both HIV-1 and M. tuberculosis. Therefore, proof-of-principle for a dual anti-HIV-1/M. tuberculosis infant
vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable
and may provide a basis for lifetime protection maintained by boosts later in life.
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Introduction
Despite great efforts in distributing anti-retroviral therapy
(ART) to infected mothers in resource-poor countries, universal
accessibility to ART remains challenging [1]. The best solution to
preventing mother-to-child transmission of human immunodefi-
ciency virus type 1 (HIV-1) via breast-feeding, which also does not
require a daily compliance, is development of an effective infant
vaccine [2]. Because Mycobacterium bovis bacillus Calmette-Gue ´rin
(BCG) is the first vaccine of the Expanded Programme for
Immunization (EPI) and technologies are now available to
genetically manipulate BCG [3–7], we proposed to use recombi-
nant BCG (rBCG) vaccine expressing an HIV-1-derived transgene
for priming of both tuberculosis (TB)- and HIV-1-specific immune
responses at birth [8]. Induced HIV-1 responses can be boosted
later by a heterologous vector such as modified vaccinia virus
Ankara (MVA) delivering the same HIV-1-derived transgene.
The main goal in preventing HIV-1 infection is development of
a vaccine eliciting broadly neutralizing antibodies (bNAb).
However, even if such a vaccine can be made [9], it will be hard
to stop some virus infection occurring e.g. through cell-
cell transmission and thus control of infection will require T
cell-mediated immune responses. A vaccine inducing strong long-
lasting T cell memory alone without bNAbs is likely to have an
impact on the HIV-1 transmission.
As the first step towards a vaccine against breast milk
transmission of HIV-1, we engineered BCG.HIVA
222 vectored
by a lysine auxotroph of the Pasteur strain of BCG and delivering
chimaeric protein designated HIVA [8]. HIVA is the first clinically
tested T cell immunogen based on consensus African HIV-1 clade
A and comprizes Gag p24-p17 and a string of CD8
+ T cell
epitopes [10,11]. In BALB/c mice, BCG.HIVA
222 induced
durable high-quality HIV-1-specific CD4
+ and CD8
+ T cell
responses. Furthermore, when used in a heterologous prime-boost
regimen, protection against surrogate virus challenge through the
HIV-1-specific responses was achieved and BCG.HIVA
222 alone
protected against aerosol challenge with M. tuberculosis [8].
MVA is currently one of the leading candidates for development
of subunit vaccines against globally important diseases. As a
capacity building and the first stage towards a more complex
regimen, the safety and immunogenicity of MVA.HIVA vaccine
alone is under evaluation in two phase I infant vaccine clinical
trials in sub-Saharan Africa [12]. The vaccine is administered to
20-week-old babies born to healthy either HIV-1-negative or
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against disseminated disease, but the protection against pulmonary
disease is much more variable, and typically lower in tropical
climates [13,14]. MVA expressing antigen 85A (Ag85A) of M.
tuberculosis was developed and shown to boost strongly BCG-
primed and naturally acquired anti-mycobacterial immunity in
humans [15–19] and is currently in a proof-of-concept phase IIb
clinical trial evaluating the safety, immunogenicity and prevention
of TB in infants primed with BCG. In the present work, we
describe construction of MVA.HIVA.85A, a dual vaccine, which
is designed to boost both M. tuberculosis- and HIV-1-specific
immune responses primed by BCG.HIVA
222.
Results
Construction of mMVA.HIVA.85A and sMVA.HIVA.85A
Novel experimental vaccines against pulmonary TB and breast
milk HIV-1 are under development. Because protection against
both of these major killers is required from birth and the first four
months of life are already very busy with the scheduled EPI
vaccinations, we thought it was advantageous to combine the anti-
TB and anti-HIV-1 vaccine strategies into a single dual vaccine
regimen consisting of priming with rBCG expressing an HIV-
1-derived immunogen and a single-vaccine-construct TB/HIV-1
boost. Construction of priming BCG.HIVA was reported
previously [8,20] and individual MVA.HIVA and MVA.85A
vaccines have been extensively clinically tested [10,19] and are
currently in clinical studies in neonates (HMcS and TH,
unpublished). The two rMVAs drive transcription of the
transgenes from early/late vaccinia virus promoter P7.5 and
employ b-galactosidase gene as a marker facilitating identification
of homologous recombinants (Fig. 1). However, both of these
functional elements are relatively large in size, and yet smaller
modified H5 (mH5) and short synthetic (ssp) promoters were
reported previously for other immunogens to support higher
protein expression levels compared to the P7.5 promoter [21,22].
Furthermore, markerless rMVA is the desirable form should this
vaccine become a licensed product. Therefore, mMVA.HI-
VA.85A and sMVA.HIVA.85A vaccines driving expression of
the two immunogens from the mH5 or ssp promoters, respectively,
were constructed (Fig. 1) and characterized with the aim to
progress the best construct to further vaccine development. In
both instances, green fluorescent protein (GFP) expression served
as a selection marker for recombinant identification and for the
mMVA.HIVA.85A vaccine, the marker gene was flanked by two
direct 200-nucleotide repeat sequences derived from the A26L
gene to facilitate excision of the marker via in cis homologous
recombination resulting in a markerless rMVA.
Short synthetic promoter supports the highest transgene
expression
The mMVA.HIVA.85A and sMVA.HIVA.85A vaccines were
first characterized as for the levels of the two transgene product
expression. Both HIVA and Ag85A proteins contain a C-terminal
epitope Pk recognized by monoclonal antibody SV5-P-k [23],
which was attached to facilitate the immunogen detection. In
addition, a mAb against p24 was employed to detect specifically
the HIVA protein. Thus, monolayers of CEF cells were infected at
MOI 1 with either the 7.5MVA.HIVA, mMVA.HIVA.85A or
sMVA.HIVA.85A vaccines and the expression of the transgene
products using the anti-Pk and p24 mAbs were readily detectable
for the ssp and mH5 promoters, while for the P7.5 promoter, the
immunofluorescence signal was fainter for anti-p24 mAb and
almost undetectable for the Pk tag (Fig. 2A); this is similar to our
previous experience [24]. To obtain more quantitative expression
data, CEF cells were infected with empty parental or rMVAs and
subjected to analysis by flow cytometry. The number and median
fluorescent intensity (MFI) of cells expressing the Pk-epitope
confirmed superior transgene expression from the sMVA.HI-
VA.85A ssp promoter (Fig. 2B and C).
Modified H5 promoter provides the most immunogenic
vaccine
To assess the dual vaccine immunogenicity, induction of MHC
class I- and II-restricted T cell responses to the HIVA and Ag85A
immunogens was compared between the dual sMVA.HIVA.85A
and single 7.5MVA.HIVA and 7.5MVA.85A vaccines at the
10
7 PFU dose delivered i.m., and found similar. For the
sMVA.HIVA,85A vaccine, specific CD8
+ T cell frequencies were
dominated by responses against the H epitope, and responses to
the other tested known MHC class I and II epitopes were clearly
detectable (Fig. 3 A). Thus, the dual vaccine can substitute for the
two single-immunogen constructs inducing both CD4
+ and CD8
+
T cell responses against both pathogens.
Next, CD8
+ T cell immunogenicity between the P7.5, mH5 and
ssp promoters was compared to guide the decision which construct
is to be taken for further development. Groups of BALB/c mice
were administered with 10
6 PFU of rMVA i.m. and their HIVA-
specific responses were assessed in a number of T cell assays 2
weeks later. Isolated splenocytes from individual mice were
stimulated in vitro with increasing concentrations of the H peptide
ranging from 0.001 mMt o1 0mM and the responding cells were
enumerated in an IFN-c ELISPOT assay. The results indicated
that mMVA.HIVA.85A was the most immunogenic vaccine
followed by sMVA.HIVA.85A, and then 7.5MVA.HIVA, al-
though only at 1 mM H peptide, a statistically significant difference
between the mH5 and ssp promoters was detected (Fig. 3 B).
Similar relative H-specific CD8
+ T cell induction was detected
using polychromatic flow cytometry confirming that the highest
frequencies of IFN-c-producing and degranulating cells were
stimulated by the mMVA.HIVA.85A vaccine (Fig. 3 C). In both
assays, the responses reached a plateau at 0.1 mM peptide H.
Next, the immunogenicity of the 7.5MVA.HIVA, mMVA.H-
VA.85A and sMVA.HIVA.85A were compared in an in vivo killing
assay, in which the target cells were pulsed with increasing
concentrations of peptide H, labeled differentially with increasing
concentrations of CFSE, mixed, transferred back into immunized
mice and re-isolated after 5 h. The in vivo specific lysis indicated
again that of the three tested vaccines, the most immunogenic was
mMVA.HIA.85A (Fig. 3 D). For the ICS and in vivo killing assays,
there was no statistically significant difference between the
frequencies of H-specific T cells induced by the mH5 and ssp
promoters. Taken together, data from three different T cell assays
showed a consistent trend that the highest H-specific T cell
responses were induced by the mMVA.HIVA.85A vaccine despite
the fact that it did not support the highest HIVA protein
expression.
BCG.HIVA
222-mMVA.HIVA.85A elicits oligofunctional anti-
HIV-1 and anti-TB responses
The mMVA.HIVA.85A vaccine was tested for T cell
immunogenicity in a combined regimen with BCG.HIVA
222.
Previously, we demonstrated induction of robust HIV-1-specific
T-cell responses in a heterologous prime-boost regimen, in which
BALB/c mice were immunized with BCG.HIVA
222 derived from
a lysine auxotroph Pasteur strain of BCG followed by a boost with
7.5MVA.HIVA [8]. However, this vaccine combination was able
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cells, but could not increase responses against M. tuberculosis.
Here, the induction of anti-Ag85A responses by the
BCG.HIVA
222 prime-mMVA.HIVA.85A boost regimen was
assessed. Thus, BALB/c mice were immunized with 10
6 CFU
of BCG.HIVA
222 i.p. or left unimmunized, and boosted with
10
6 PFU i.m. of single or mixed rMVAs 12 weeks later or left
unboosted. To control for the possible increased MVA adjuvan-
tation given in the 7.5MVA.HIVA and 7.5MVA.85A group,
additional 10
6 PFU of empty parental MVA was added to the
single rMVA immunizations to make the total number of
poxvirus PFUs given to each mouse comparable. MHC class I
and II-restricted T cell responses induced by immunogens HIVA
and Ag85A were analyzed 2 weeks after the last vaccination and
a number of observations was made. Thus, BCG.HIVA
222 alone
induced weak CD8
+ T cell responses to P15 and weak responses
to Purified Protein Derivative (PPD), the latter mainly generated
by CD4
+ T cells (Fig. 4). The P15-specific responses were strongly
boosted by both the 7.5MVA.85A and mMVA.HIVA.85A
vaccines (Fig. 4 A, Viii and ix). However, the lower 10
6-PFU
dose of 7.5MVA.85A and mMVA.HIVA.85A alone did not
prime any significant Ag85A-specific T cells (Fig. 4 A, iv and v).
Interestingly, there was a trend of augmenting the PPD responses
by the prime-boost regimens (Fig. 4 A, viii and ix), while
frequencies of P11-specific T cells remained low. Consistent with
previous reports [25,26], no detectable HIVA-specific T cell
responses were elicited by BCG.HIVA
222 alone (Fig. 4 A, i). A
single injection of 7.5MVA.HIVA induced a typical 100- to 300-
SFU response reflecting the fact that rMVA is not a strong
priming vaccine (Fig. 4 A, ii and iv). This frequency was
approximately doubled by using the mH5 promoter (Fig. 4 A, iii
and v). A similar 2-fold increase in H-specific responses was
achieved by BCG.HIVA
222 priming of the 7.5MVA.HIVA alone
responses, but not for the combination 7.5MVA.HIVA+7.5M-
VA85A boost (Fig. 4 A, vi and viii). A smaller BCG.HIVA
222
priming effect was detected for the mH5 promoter-driven HIVA
expression (Fig. 4 A, vii and ix). No regimen induced detectable
HIVA-specific MHC class II-restricted responses. Finally, robust
T cell responses against both HIVA and Ag85A antigens were
elicited by the BCG.HIVA
222-mMVA.HIVA.85A regimen (Fig. 4
A, ix), an important initial milestone for the pre-clinical
development of this approach. Oligofunctionality of the vac-
cine-induced CD8 T cell responses was confirmed by a multi-
colour flow cytometry assessing production of IFN-c, TNF-a and
CD107a (Fig. 4 B).
Discussion
In this report, we describe construction of vaccine MVA.HI-
VA.85A, which expresses immunogens derived from HIV-1 and
M. tuberculosis, and demonstrate its dual T cell immunogenicity in
BALB/c mice following a prime with BCG.HIVA
222, recombi-
nant BCG expressing the same HIV-1 immunogen. A self-excising
GFP gene was used to construct a markerless MVA-vectored
vaccine making it more suitable for Good Manufacturing Practice
(GMP) production. Overall, we demonstrate that BCG.HIVA
222
prime-MVA.HIVA.85A boost strategy may offer a neonate
vaccination platform combining induction of T cell responses
against two major killers, AIDS and TB, into a single regimen.
This is an early proof-of-concept study indicating that this
approach is worthy of further pursuit.
In recent years, MVA has been used extensively as a non-
replicating vaccine vector for delivery of immunogens derived
from diverse pathogens [27]. Its ability to boost consistently and
strongly T cell responses against the transgene products in humans
has been shown by experimental vaccines against AIDS,
tuberculosis, malaria and cancer [10,28–30]. MVA has a complex
genome and its promoters are classified based on the timing of
gene expression into early, intermediate and late. This has an
impact on the immunogenicity through multiple mechanisms,
which interfere with presentation of late T-cell epitopes [31–37].
Here, we compared three conventional early/late promoters P7.5,
mH5 and ssp in combination with the HIVA and Ag85A open-
reading frames for maximum T cell induction. The P7.5 promoter
is active both early and late in the MVA life cycle and by
immunofluorescence often yields low to undetectable levels of the
Figure 1. Schematic representation of inserted DNA fragments. Expression cassettes containing genes coding for immunogens HIVA and
Ag85 using either b-galactosidase or GFP markers were inserted into the tk locus of the MVA genome by homologous recombination directed by the
left and right tk flanking regions (tkL and tkR). Transcription of the two immunogens was controlled by either P7.5, modified H5 (mH5) or short
synthetic (ssp) promoters. In the mH5 version, the GFP gene is flanked by two homologous repeats (A26L), which facilitate removal of the selection
marker. Proteins/epitopes are shown in bold, while promoters are indicated using a regular font style.
doi:10.1371/journal.pone.0020067.g001
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a number of clinical vaccines, especially if the T cell responses
were well primed, e.g. by HIV-1 infection [10,28,30]. The mH5
promoter is stronger than P7.5 and has an early bias, while the ssp
promoter is the strongest of the three with a bias towards late
expression [21,22,40]. We found that ssp promoter led to the
highest level of protein expression, however, very high expression
may lead to genetic instability as reported previously for some
transgenes [21,40,41]. Nevertheless, stable recombinant MVAs
have been prepared expressing proteins from two ssp promoters
pointing away from [42] as well as towards each other [43]. Thus,
genetic stability of ssp-controled transgenes is likely to be specific
for each particular combination of immunogen and/or integration
sites in the MVA genome [44,45].
Next, the efficiency of T cell induction was investigated in the
BALB/c mice and showed that vaccination with either mixed
single-transgene or dual vaccines elicited comparable T cell
responses specific for the HIVA and Ag85A proteins. Further-
more, a direct comparison of the P7.5, mH5 and ssp rMVAs
showed a consistent trend in three different functional tests, the
IFN-c/CD107a ICS, IFN-c ELISPOT and in vivo killing assays,
that superior frequency and functionality of specific T cells against
Figure 2. Protein expression from recombinant MVAs in CEF cells. CEF cells were infected with indicated viruses at MOI 1 for 16 h. (A) Cell
were stained either for Gag p24 or Pk tag (on HIVA and Ag85A) expression as shown above and analyzed under fluorescent microscope. Also, the
relative levels of protein expression were assessed using flow cytometry and shown either as a (B) histogram for parental MVA (black), 7.5MVA.HIVA
(red), mMVA.HIVA.85A (blue) or sMVA.HIVA.85A (green) viruses or (C) expressed as mean fluorescent intensity (MFI) 6 SD (C). The figure shows
representative data of three independent experiments.
doi:10.1371/journal.pone.0020067.g002
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outcome concurs with previously published work [22]. When the
novel rMVA vaccine was tested in a heterologous BCG.HIVA
222
prime-mMVA.HIVA.85A regimen, elicitation of robust HIV-1-
specific CD8
+ and TB-specific CD4
+ T cell responses were
detected. Although the anti-HIV-1 responses showed only a trend
of enhancement by the combined regimen relative to unprimed
mMVA.HIVA.85A, a boost was readily detected for the Ag85A
response. HIVA-specific enhancement was observed in mice for
single-immunogen as described for 7.5MVA.HIVA before [8]; this
may be due to the weaker vaccinia virus promoter, which ‘‘leaves
room’’ for improvement in this model. Overall, we find induction
of the dual HIV-1 and TB-specific responses encouraging for
further vaccine and regimen optimizations. Several studies used
successfully rBCG in heterologous prime-boost regimens with
other vaccine modalities, whereby poxviruses, adenoviruses and
virus-like particles as vectors delivered a strong boost for BCG-
primed responses against the shared transgene products
[3,20,46,47]. MVA.85A delivered a particularly strong boost for
BCG-primed anti-Ag85A T cells [15,28,39] and in mice,
intranasally administered MVA.85A increased protective efficacy
of BCG against M. tuberculosis challenge [39]. Improved efficacy by
MVA.85A over BCG vaccine alone was also shown in non-human
primates and cattle [48,49]. To prepare a BCG.HIVA vaccine
compliant with Good Laboratory Practice, endosomal escape
strain of BCG AERAS-401 derived from the Danish SSI-1331
parent was utilized [20]. In combination with MVA.HIVA and
ovine atadenovirus-vectored OAdV.HIVA [50] vaccines,
BCG.HIVA
401 primed for robust HIV-1-specific T cell responses
[20]. However, in macaque neonates, the BCG.HIVA
401 prime-
MVA.HIVA boost regimen was only weakly immunogenic [51]. It
is worth noting that interspecies differences in T cell responsive-
ness to BCG may influence the outcome of immunizations and
therefore it is not clear how adult mouse data transfer to non-
human primate and human neonates; it remains a possibility that
human neonates actually respond better to a rBCG vaccine than
the model systems.
BCG given to immunocompromized individuals may cause a
disseminated disease. Thus, the current WHO guidelines recom-
mend withholding BCG vaccination until the HIV-1 negativity is
confirmed (if the infrastructure to carry out testing exists) [52].
However, because the risk of TB is so high, HIV-1-negative babies
born to HIV-1-positive mothers are recommended to receive BCG
and so there would be use for BCG.HIVA. Furthermore, the
lysine auxotroph strain of BCG Pasteur used here [53] may
provide addition safety and genetic stability [54].
In conclusion, MVA continues to feature prominently in clinical
trials of recombinant vaccines against major global diseases. Here,
we have constructed a novel prototype vaccine MVA.HIVA.85A,
which is markerless and therefore compatible with GMP
manufacture, and combines stimulation of oligofunctional T cell
responses against both HIV-1 and M. tuberculosis. Furthermore, we
demonstrate that a dual platform against AIDS and TB consisting
of BCG.HIVA prime-MVA.HIVA.85A boost is in principle
possible, although particularly the HIV-1 immunogen may be
further refined e.g. by using conserved regions of the HIV-1
proteome, which may better control diverse HIV-1 strains
circulating in the target population and HIV-1 escape from
immune responses [55]. This work is a logical extension of the
current efforts in developing strategies against these two major
killers and timely given the WHO’s interest in improving the
currently recommended infant vaccine schedules. Of course, the
only relevant proof of efficacy can only come from protection
studies in human neonates.
Figure 3. Induction of HIV-1- and M. tuberculosis-specific T cell responses. (A) Groups of 4 BALB/c mice were immunized with 10
7 PFU i.m. of
either 7.5MVA.HIVA, 7.5MVA.85A or sMVA.HIVA.85A, sacrificed 2 weeks later and splenocytes from individual mice were analyzed for IFN-c production
following peptide stimulation. Data are represented as means 6 SD. (B–C) Groups of 4 BALB/c mice were immunized i.m. with 10
5 PFU of either
7.5MVA.HIVA (triangles), mMVA.HIVA.85A (circles) or sMVA.HIVA.85A (squares) vaccines. Two weeks later, mice were sacrificed and the ability of
splenocytes from individual animals to respond to increasing amounts of peptide H was assessed in an IFN-c ELISPOT (B), ICS (C) and in vivo killing
(D) assays. Mean 6 SD are shown. Only stimulation with 1 mM H peptide in an IFN-c ELISPOT assay provided a statistically significant difference
(p=0.04) between frequencies induced using the mH5 and ssp promoters.
doi:10.1371/journal.pone.0020067.g003
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Preparation of dual-insert recombinant MVAs
The construction of transfer plasmids directing the insertion of
transgenes under the control of either the mH5 or ssp promoters
[21,22] into the thymidine kinase (tk) locus of the MVA genome is
described in detail in elsewhere generating mMVA.HIVA.85A
and sMVA.HIVA.85A, respectively (DPhil Thesis, Richard
Hopkins, University of Oxford, 2010). rMVAs were rescued by
infecting a semi-confluent monolayer of chicken embryo fibroblast
(CEF) cells grown in Dulbeco’s Modified Eagles Medium
supplemented with 10% FBS, penicillin/streptomycin and gluta-
mine, (DMEM-10) with parental MVA expressing the red
fluorescent protein (RFP) at multiplicity of infection (MOI) of
Figure 4. Induction of robust HIV-1- and M. tuberculosis-specific T cells by the BCG.HIVA
222 prime - mMVA.HIVA.85A boost regimen.
(A) Groups of 5 BALB/c mice received either BCG.HIVA
222 (B
222)( i and vii–ix) or no vaccine (ii–v) on week 0, followed by rMVA(s) (ii–ix) as indicated
on the top of the graphs or no vaccine (i) at week 12. On week 16, mice were killed and their HIV-1 (H and II)- and mycobacterium (P11, P15 or PPD)-
specific responses were determined in an IFN-c ELISPOT assay using MHC class I (H and P11) or class II (II and P15)-restricted peptides. Results are
shown as individual animal responses (black dots) with group means (horizontal bars). (B) The functionality of vaccine-induced CD8
+ T cell responses
was assess in a multicolour intracellular cytokine staining assay. The group mean frequencies of single-, double- or triple-cytokine-producing H- or
P11-specific cells following background subtraction are shown for the three regimens indicated above the graphs.
doi:10.1371/journal.pone.0020067.g004
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GFP gene as a marker 1 h later. Note, that a successful
recombination into the tk locus exchanges the parental RFP for
GFP of the recombinant (Gilbert, unpublished). Forty-eight h post
transfection, the total virus was harvested and used to re-infect
fresh CEF monolayer. rMVA was subjected to at least five rounds
of plaque purification, based on GFP expression and the absence
of RFP. Removal of the parental MVA was confirmed by PCR.
Master virus stock was grown, purified on a 36% sucrose cushion,
titred and stored at 280uC until use. In the mMVA.HIVA.85A,
the GFP gene flanked by two small regions of homology, which
allowed GFP removal in a homologous recombination event
during further passaging and generation of a markerless vaccine
(Fig. 1).
Preparation of BCG.HIVA
222 vaccine
Construction and preparation of the BCG.HIVA
222 stock was
described previously [26]. Briefly, mycobacterial cultures were
grown in Middlebrook 7H9 broth medium or on Middlebrook
agar 7H10 medium supplemented with albumin-dextrose complex
(ADC, Difco) and containing 0.05% Tween 80 and 25 mg/ml
kanamycin. The L-lysine monohydrochloride (Sigma) was dis-
solved in distilled water and used at a concentration of 40 mg/ml.
Quantitation of HIVA and Ag85A protein expression by
immunofluorescence and flow cytometry
Three hundred thousand CEF cells were infected with rMVA at
1 MOI in a single well of a six-well plate with or without a glass
slide. After 16 h, cells not growing on a glass slide were detached
and transferred into to a test tube. Both suspended and glass-
attached CEF populations were fixed, permeabilized with 220uC
methanol for 5 min, washed 36with PBS, blocked for 30 min in
PBS-10% FCS at room temperature, incubated with primary anti-
HIV-1 Gag p24 antibody (NIH AIDS Reagents) at 1 mg/ml at
room temperature for 2 h and washed with PBS 36. The
secondary antibody, Alexa-Fluor 594-conjugated goat anti-mouse
mAb (Molecular Probes, Invitrogen), was then added at 5 mg/ml
in combination with a primary anti-Pk antibody conjugated to
FITC (Abcam) in PBS-1% FCS at room temperature for 2 h, and
the cells were washed 36with PBS. Cells mounted on a glass slide
were covered with Vector-Shield containing DAPI (Vector
Laboratories) and photographed on a Zeiss fluorescence micro-
scope, while cells in suspension were acquired on a Cyan FACS
machine (Dako) and analyzed using Flowjo software (Tree Star).
Mouse immunizations and isolation of splenocytes
Groups of 5- to 6-week-old female BALB/c mice were
immunized either without anaesthesia intraperitoneally (i.p.) with
BCG.HIVA
222, or under general anaesthesia intramuscularly (i.m)
with rMVA at doses and schedules outlined in the figure legends.
On the day of sacrifice, individual spleens were collected and
splenocytes were isolated by pressing spleens through a cell
strainer (Falcon) using a 5-ml syringe rubber plunger. Following
the removal of red blood cells with RBC Lysis Buffer (Sigma), the
splenocytes were washed and resuspended in RPMI 1640
supplemented with 10% FCS, penicillin/streptomycin (R-10).
Ethics statement
All animal procedures and care conformed strictly to the United
Kingdom Home Office Guidelines under The Animals (Scientific
Procedures) Act 1986. The protocol was approved by the local
Research Ethics Committee (Clinical Medicine, University of
Oxford). Experiments were carried out under Project Licence
no. 30/2406 held by TH with a strict implementation of the
Replacement, Reduction and Refinement (3Rs) principles.
Peptides
Peptides RGPGRAFVTI designated H [56] and derived from
HIVA, and EWYDQSLGSVVMPVGGQSSF designated P11
and derived from Ag85A [57] were used to investigate the MHC
class I-restricted responses. A pool of three peptides MHQ-
ALSPRTLNAQVKVIEEK, NPPIPVGDIYKRWIILGLNK, FR-
DYVDRFFKTLREAQATQE designated II [8] and a single
peptide TFLTSELTGWLQANRHVKPT designated P15 [57]
were used to analyze the MHC class II-restricted responses
induced by immunogens HIVA and Ag85A, respectively. All
peptides were synthesized in an in-house facility (Weatherall
Institute of Molecular Medicine, Oxford, UK), dissolved in
DMSO (Sigma) at a concentration of 10 mg/ml, and stored at
280uC. The final assay concentration for individual peptides was
4 mg/ml unless otherwise stated. PPD (Statens Serum Institute,
Copenhagen) was used to assess the immunogenicity of BCG.
Ex vivo IFN-c ELISPOT assay
The ELISPOT assay was performed using the IFN-c ELISPOT
kit (Mabtech) as described previously [58]. The ELISPOT plate
membranes (Millipore) were coated with purified anti-mouse IFN-
c antibody diluted in carbonate-bicarbonate buffer (Sigma) to a
final concentration of 5 mg/ml at 4uC overnight, washed once in
R-10, and blocked for 2 h with R-10. A total of 2.5610
5
splenocytes were added to each well, stimulated with HIVA- or
Ag85A-derived peptides or PPD RT49 (Statens Serum Institute,
Denmark) or left un-stimulated.for 16 h at 37uC, 5% CO2 and
lyzed by incubating 26 with deionized water for 5 min. Wells
were then washed 36with PBS 0.05% Tween-20, incubated for
2 h with a biotinylated anti-IFN-c antibody diluted in PBS 2%
FCS to a final concentration of 2 mg/ml, washed 36 in PBS
0.005% Tween-20 and incubated with 50 mg/ml horseradish
peroxidase-conjugated to avidin in PBS 2% FCS. Wells were
washed 46with PBS 0.005% Tween-20 and 26with PBS before
incubating with an AEC substrate solution [3-amino-9-ethyl-
carbazole (Sigma) dissolved at 10 mg/ml in Dimethyl formalde-
hyde and diluted to 0.333 mg/ml in 0.1 M acetate solution
(148 ml 0.2 M acetic acid and 352 ml 0.2 M sodium acetate in
1 liter pH 5.0) with 0.005% H2O2]. After 5–10 min, the plates
were washed with tap water, dried and the resulting spots were
counted using an ELISPOT reader (Autoimmune Diagnostika
GmbH). All samples were analyzed in duplicates.
Polychromatic flow cytometry assay
Two million splenocytes per well of a 96-well round-bottomed
plate (Falcon) were pulsed with peptides together with anti-
CD107a/b-FITC antibody and incubated at 37uC, 5% CO2 for
90 min before addition of GolgiStop. After further 5 h, the
reaction was terminated, the cells were washed with FACS wash
buffer (PBS, 2% FCS, 0.01% Azide) and blocked with anti-CD
16/32 at 4uC for 30 min. All subsequent antibody incubations
were performed using the same conditions. The cells were washed
26 and stained with: 25 ng of anti-mouse CD19-Pacific Blue;
100 ng anti mouse-CD3 PerCP-Cy5.5 (eBioscience); 200 ng anti-
mouse CD8a-PE-Texas Red (Abcam). The cells were washed 26
with FACS buffer and permeabilized with BD Cytofix/Cytoperm
(BD Biosciences), washed 26with BD Perm/Wash buffer, before
staining with 25 ng of anti-mouse IFN-c -PE-Cy-7. Cells were
washed with Perm/Wash buffer and fixed with CellFIX and
stored at 4uC until analysis. Samples were acquired on Cyan
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software (Tree Star).
In vivo killing assay
To prepare the targets, naı ¨ve 5- to 6-week-old female BALB/c
mice were sacrificed and the splenocytes were isolated as described
above [26]. The splenocytes were then incubated without or with
0.1, 1 or 10 mM peptide H in R-10, washed 36and subsequently
labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE, Molecular Probes) at the following concentrations for the
deferentially pulsed populations: 4 nM - no peptide; 16 nM–
0.1 mM peptide H; 80 nM–1 mM peptide H; 160 nM–10 mM
peptide for at 37uC for 15 min and a further 15 min in fresh
medium. Peptide-pulsed splenocytes were washed 36 and
combined for intravenous adoptive transfer. Each animal received
approximately 2610
6 cells of each population and was sacrificed
5 h later, and its splenocytes were isolated and analyzed using flow
cytometry. Cytotoxicity was calculated as described previously
[59]: Adjusted % survival=1006(% survival of peptide-pulsed
targets/mean % survival of irrelevant peptide pulsed cells),
followed by the calculation of % specific lysis=100 – adjusted
% survival.
Statistical analysis
Statistical significance was determined using an unpaired
Student’s t-test with a two-tailed distribution on group immuni-
zation data using Prism software. Data were presented as mean 6
SD unless otherwise stated. Differences were considered as
significant at p#0.05.
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